Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction

European Journal of Pharmacology

Volumn 737, Issue , 2014, Pages 77-84

  Soraya, Hamid ^a   Clanachan, Alexander S ^b   Rameshrad, Maryam ^c   Maleki Dizaji, Nasrin ^c   Ghazi Khansari, Mahmoud ^d   Garjani, Alireza ^c  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AMP activated protein kinase; Inflammation; Metformin; Myocardial infarction; Toll like receptor

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; ISOPRENALINE; MESSENGER RNA; METFORMIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TLR4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; ISOPROTERENOL-INDUCED MYOCARDIAL INFARCTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TLR4 GENE; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG THERAPY; GENETICS; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEMODYNAMICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; TIME; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HEMODYNAMICS; INTERLEUKIN-6; ISOPROTERENOL; MALE; METFORMIN; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHORYLATION; RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84901733607     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.05.003     Document Type: Article

References (39)

1. F. Arslan, M.B. Smeets, L.A.J. O'Neill, B. Keogh, P. McGuirk, L. Timmers, C. Tersteeg, I.E. Hoefer, P.A. Doevendans, G. Pasterkamp, and D.P.V. De Klejin Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody Circulation 121 2009 80 90
2. T.V. Arumugam, E. Okun, S.C. Tang, J. Thundyil, S.M. Taylor, and T.M. Woodruff Toll-like receptors in ischemia-reperfusion injury Shock 32 2009 4 16
3. G.S. Bhamra, D.J. Hausenloy, S.M. Davidson, R.D. Carr, M. Paiva, A.M. Wynne, M.M. Mocanu, and D.M. Yellon Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening Basic Res. Cardiol. 103 2008 274 284
4. J.R.B. Dyck, and G.D. Lopaschuk AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol. 574 2006 95 112 (Pubitemid 43905800)
5. Y. Feng, H. Zhao, X. Xu, E.S. Buys, M.J. Raher, J.C. Bpassa, H. Thibault, M. Scherrer-Crosbie, U. Schmidt, and W. Chao Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice Am. J. Physiol. Heart Circ. Physiol. 295 2008 1311 1318
6. Y. Fischer, J. Thomas, P. Rosen, and H. Kammermeier Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats Endocrinology 136 1995 412 420
7. C.D.L. Folmes, C.S. Wagg, M. Shen, A.S. Clanachan, R. Tian, and G.D. Lopaschuk Suppression of 5-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts Am. J. Physiol. Heart Circ. Physiol. 297 2009 313 321
8. N.G. Frangogiannis, C.W. Smith, and M.L. Entman The inflammatory response in myocardial infarction Cardiovasc. Res. 53 2002 31 47 (Pubitemid 34020764)
9. S. Frantz, and J. Bauersachs Toll-like receptors: emerging therapeutic targets for heart failure Heart Metab. 47 2010 19 22
10. A. Garjani, S. Andalib, S. Biabani, H. Soraya, Y. Doustar, A. Garjani, and N. Maleki-Dizaji Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat Eur. J. Pharmacol. 666 2011 135 141
11. S. Gundewar, J.W. Calvert, S. Jha, I. Toedt-Pingel, S. Yong Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian, and D.J. Lefer Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure Circ. Res. 104 2009 403 411
12. D.G. Hardie, S.A. Hawley, and J.W. Scott AMP-activated protein kinase - development of the energy sensor concept J. Physiol. 574 2006 7 15 (Pubitemid 43905792)
13. Y. Jiang, W. Huang, J. Wang, Z. Xu, J. He, X. Lin, Z. Zhou, and J. Zhang Metformin plays a dual role in MIN6 pancreatic β cell function through AMPK-dependent autophagy Int. J. Biol. Sci. 10 2014 268 277
14. G. Kewalramani, D. An, M.S. Kim, S. Ghosh, D. Qi, A. Abrahani, T. Pulinilkunnil, V. Sharma, R.B. Wambolt, M.F. Allard, S.M. Innis, and B. Rodriques AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes J. Mol. Cell. Cardiol. 42 2007 333 342 (Pubitemid 46135612)
15. D. Kirpichnikov, S.I. McFarlane, and J.R. Sowers Metformin an update Ann. Intern. Med. 137 2002 25 33
16. S. Korkmaz, T. Radovits, E. Barnucz, K. Hirschberg, P. Neugebauer, S. Loganathan, G. Veres, S. Pali, B. Seidel, S. Zollner, M. Karck, and G. Szabo Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury Circulation 120 2009 677 686
17. R.J. Legtenberg, R.J. Houston, B. Oeseburg, and P. Smits Metformin improves cardiac functional recovery after ischemia in rats Horm. Metab. Res. 34 2002 182 185 (Pubitemid 34553530)
18. M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory cytokines and postmyocardial infarction remodeling Circ. Res. 94 2004 1543 1553 (Pubitemid 38856961)
19. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, and D.J. Drucker GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
20. M.A. Omar, S. Verma, and A.S. Clanachan Adenosine-mediated inhibition of 5′-AMP-activated protein kinase and p38 mitogen-activated protein kinase during reperfusion enhances recovery of left ventricular mechanical function J. Mol. Cell. Cardiol. 52 2012 1308 1318
21. M.R. Owen, E. Doran, and A.P. Halestrap Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem. J. 348 2000 607 614 (Pubitemid 30410251)
22. J.I. Oyama, C. Blais Jr., X. Liu, M. Pu, L. Kobzik, R.A. Kelly, and T. Bourcier Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice Circulation 109 2004 784 789 (Pubitemid 38222900)
23. M.A. Paiva, L.M. Goncalves, L.A. Providencia, S.M. Davidson, D.M. Yellon, and M.M. Mocanu Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction Cardiovasc. Drugs Ther. 24 2010 25 32
24. M.W. Pfaffl A new mathematical model for relative quantification in real time RT-PCR Nucleic Acids Res. 29 2001 2002 2007
25. R.R. Russell, J. Li, D.L. Coven, M. Pypaert, C. Zechner, M. Palmeri, F.J. Giordano, J. Mu, M.J. Birnbaum, and L.H. Young AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury J. Clin. Invest. 114 2004 495 503 (Pubitemid 39572099)
26. H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, S. Takashima, S. Sanada, M. Sugimachi, K. Komamura, N. Mochizuki, and M. Kitakaze Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase Circulation 119 2009 2568 2577
27. L. Solskov, B. Lofgren, S.B. Kristiansen, N. Jessen, R. Pold, T.T. Nielsen, H.E.B.O. Schmitz, and S. Lund Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 h after administration Basic Clin. Pharmacol. Toxicol. 103 2008 82 87 (Pubitemid 351874532)
28. H. Soraya, A. Khorrami, A. Garjani, N. Maleki-Dizaji, and A. Garjani Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats Pharmacol. Rep. 64 2012 1476 1484
29. H. Soraya, S. Farajnia, S. Khani, M. Rameshrad, A. Khorrami, A. Banani, N. Maleki-Dizaji, and A. Garjani Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected? Int. Immunopharmacol. 14 2012 785 791
30. S. Steffens, F. Montecucco, and F. Mach The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury Thromb. Haemost. 102 2009 240 247
31. L. Timmers, G. Pasterkamp, V.C. de Hoog, F. Arslan, Y. Appelman, and D.P.V. de Kleijn The innate immune response in reperfused myocardium Cardiovasc. Res. 94 2012 276 283
32. L. Timmers, J.P.G. Sluijter, J.K. van Keulen, I.E. Hoefer, M.G.J. Nederhoff, M.J. Goumans, P.A. Doevendans, C.J.A. van Echteld, J.A. Joles, P.H. Quax, J.J. Piek, G. Pasterkamp, and D.P.V. de Kleijn Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction Circ. Res. 102 2008 257 264 (Pubitemid 351674064)
33. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
34. S. Vecchio, A. Giampreti, V.M. Petrolini, D. Lonati, A. Protti, P. Papa, C. Rognoni, A. Valli, L. Rocchi, L. Rolandi, L. Manzo, and C.A. Locatelli Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy Clin. Toxicol. (Phila.) 52 2014 129 135
35. B. Viollet, B. Guigas, N.S. Garcia, J. Leclerc, M. Foretz, and F. Andreeli Cellular and molecular mechanisms of metformin: an overview Clin. Sci. (Lond.) 122 2012 253 270
36. H.J. Whittington, A.R. Hall, C.P. McLaughlin, D.J. Hausenloy, D.M. Yellon, and M.M. Mocanu Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon Cardiovasc. Drugs Ther. 27 2013 5 16
37. M. Yin, I.C.C. van der Horst, J.P. van Melle, C. Qian, W.H. van Gilst, H.H.W. Sillje, and R.A. de Boer Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure Am. J. Physiol. Heart Circ. Physiol. 301 2011 459 468
38. C.X. Zhang, S.N. Pan, R.S. Meng, C.Q. Peng, Z.J. Xiong, B.L. Chen, G.Q. Chen, F.J. Yao, Y.L. Chen, Y.D. Ma, and Y.G. Dong Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats Clin. Exp. Pharmacol. Physiol. 38 2011 55 62
39. X. Zhao, J.W. Zmijewski, E. Lorne, G. Liu, Y.J. Park, Y. Tsuruta, and E. Abraham Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury Am. J. Physiol. Lung Cell. Mol. Physiol. 295 2008 497 504